Zogenix Inc. has acquired Brabant Pharma
| Target Company Name |
Brabant Pharma |
|---|---|
| Target Country |
United Kingdom |
| Description | Brabant's assets include worldwide development and commercialisation rights to Brabafen, low-dose fenfluramine, for the treatment of Dravet Syndrome. |
| Global M&A Offices |
Zeus
(Global M&A United Kingdom)
|
| Global M&A Advisory | Advisor |
